I Mab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from I mab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In I Mab Today - Breaking & Trending Today

Needham & Company LLC Reaffirms Buy Rating for I-Mab (NASDAQ:IMAB)

I-Mab (NASDAQ:IMAB – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research report issued on Friday, Benzinga reports. They currently have a $6.00 target price on the stock. Needham & Company LLC’s price objective suggests a potential upside of 231.49% from the stock’s previous […] ....

United States , Piper Sandler , Goldman Sachs Group Inc , Needham Company , Cantor Fitzgerald , Blackrock Inc , America Corp , Jpmorgan Chase Co , Company Profile , Vanguard Group Inc , Get Free Report , Mab Trading Down , Sachs Group , I Mab Daily , I Mab , Nasdaq Imab , Reiterated Rating , Needham Amp Company Llc ,

I-Mab to Divest Chinese Unit for Up to $80M

By Rob Curran Biotech concern I-Mab agreed to sell its Chinese unit to affiliate I-Mab Biopharma (Hangzhou)for up to $80 million after contingencies, and it. ....

San Diego , United States , Hong Kong , Biopharma Hong Kong , Joseph Skelton , Pamela Klein , Jingwu Zang , Richard Yeh , Raj Kannan , Rob Curran , Andrew Zhu , I Mab Biopharma , I Mab Chief Executive Raj Kannan , I Mab Biopharma Hong Kong , I Mab Hong Kong , Article Normal , Biotechnology Services , Healthcare Life Sciences , Biological Therapy , Healthcare Provision , Ownership Changes , Corporate Actions , Corporate Industrial News , Content Types , Factiva Filters , C Amp Ampe Industry News Filter ,

Reviewing I-Mab (NASDAQ:IMAB) and Cerevel Therapeutics (NASDAQ:CERE)

I-Mab (NASDAQ:IMAB – Get Free Report) and Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability. Institutional & Insider Ownership 22.6% of I-Mab shares are […] ....

United Kingdom , United States , Kalbe Genexine Biologics , Abbvie Ireland Unlimited Company , Sinopharm Group Co , Jumpcan Pharmaceutical Group , Cerevel Therapeutics Holdings Inc , Get Free Report , Cerevel Therapeutics , Giveni Mab , Cerevel Therapeutic , Genexine Biologics , Sinopharm Group , Therapeutics Holdings , I Mab Daily , I Mab , Nasdaq Imab , Stock Comparison , Stock Analysis ,

Cantor Fitzgerald Reaffirms Overweight Rating for I-Mab (NASDAQ:IMAB)

Cantor Fitzgerald restated their overweight rating on shares of I-Mab (NASDAQ:IMAB – Free Report) in a research report report published on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for I-Mab’s FY2023 earnings at ($1.85) EPS and FY2024 earnings at ($1.14) EPS. Separately, Needham & Company LLC dropped their price target on shares of […] ....

Hong Kong , Panagora Asset Management Inc , Fund Management Hong Kong Co , Cantor Fitzgerald , Citigroup Inc , Jpmorgan Chase Co , Company Profile , E Fund Management Hong Kong Co , Needham Company , Acadian Asset Management , Free Report , Fund Management Hong Kong , Asset Management , Panagora Asset Management , Get Free Report , I Mab Daily , I Mab , Nasdaq Imab , Reiterated Rating ,

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for Immunotherapy o ....

South Korea , Xuejun Liu , Jaeho Jung , Tyler Ehler , Bio Kosdaq , Gigi Feng , Drug Administration , Exchange Commission , Orphan Drug Designation , Private Securities Litigation Reform Act , Bispecific Antibody , Gastric Cancer , Poster Presentations , I Mab ,